权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Beta Cell Heterogeneity in the Interferon Alpha Response

干扰素α反应中的β细胞异质性

基本信息

批准号：
10751684
负责人：
Leslie Elaine Wagner
金额：
$ 4.77万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-06-08 至 2025-06-07
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10751684
关键词：
ANXA5 gene Acute Address Advisory Committees Apoptosis Apoptotic Area Autoimmune Diseases Autoimmune Responses Award Beta Cell Biosensor Cells Communication Comprehension Coupled Cytoplasm Detection Development Diabetes Mellitus Disease Disease Progression Endoplasmic Reticulum Enterovirus Environment Event Fluorescence-Activated Cell Sorting Functional disorder Funding Future Gene Expression Genes Genetic Predisposition to Disease Genetic Risk Goals Grant Heterogeneity Human Hydrogen Peroxide Immune Immunofluorescence Immunologic In Vitro Indiana Individual Induction of Apoptosis Inflammatory Innate Immune System Insulin Insulin-Dependent Diabetes Mellitus Interferon alpha Interferons Interleukin-1 beta Islets of Langerhans Knowledge Label Laboratories Link MHC Class I Genes Metabolic Diseases Microscopy Mind Mitochondria Molecular Profiling Monitor Mus Nitric Oxide Oral Oranges Organelles Oxidative Stress Oxidative Stress Induction Pancreas Pathogenesis Patients Population Predisposition Prevalence Production Proteins Publishing Reactive Oxygen Species Research Research Personnel Residual state Risk Role Scientist Slice Stress Superoxides Techniques Testing Therapeutic Training United States National Institutes of Health Universities Virus Diseases Work Writing career development cytokine design diabetes pathogenesis diabetogenic differential expression dihydroethidium disorder prevention early childhood early onset endoplasmic reticulum stress experimental study improved in vivo insight insulin dependent diabetes mellitus onset intravital imaging islet medical schools mouse model non-diabetic novel novel therapeutics overexpression prevent ratiometric response single-cell RNA sequencing stressor therapeutic target transcriptomics

项目摘要

1 PROJECT SUMMARY 2 Type 1 Diabetes (T1D) is an autoimmune disease characterized by destruction of insulin producing β-cells due 3 to a combination of genetic risk and an unknown environmental trigger. A leading hypothesis for the 4 environmental trigger is viral infection, during which the innate immune system releases various cytokines and 5 interferons. Interferon alpha (IFN-α) has been long implicated in disease pathogenesis, with its presence 6 observed in islets of donors with early-onset T1D. It has also been shown that IFN-α induces ER stress, MHC 7 class 1 overexpression, and islet apoptosis, classical hallmarks of T1D development. For many years it was 8 thought that all β-cells were destroyed in individuals with T1D. Recently, this dogma has been challenged with 9 the discovery of residual insulin positive β-cells in donors with long-standing T1D. This suggests that β-cells are 10 heterogeneous, with one population of β-cells able to survive conditions of high stress. With these observations 11 in mind, the central goal of this proposal is to understand mechanisms behind heterogeneity of human β-cell 12 ROS response following IFN-α insult. I hypothesize that ROS accumulating β-cells, termed ‘ROSponders’ 13 contain a unique molecular signature that promotes this heterogeneity in ROS accumulation, causing this subset 14 of cells to be more susceptible to oxidative stress and apoptosis. I will test this hypothesis through three specific 15 aims. Experiments in aim 1 are designed to characterize the molecular signature of ROSponders, with the goal 16 of identifying what makes them more susceptible to this ROS accumulation. In aim 2, I will determine the origin 17 of accumulating ROS. In aim 3, I will determine the fate of ROSponders through longitudinal intravital imaging. 18 With completion of these aims, the goal is to determine the mechanism and consequence of this observed 19 heterogeneity in ROS response. Importantly, through transcriptomics, this work will aim to identify novel targets 20 to prevent β-cell dysfunction under diabetogenic conditions, allowing for the development of future therapeutics 21 for disease prevention and/or treatment. A comprehensive understanding of islet function in early diabetes 22 pathogenesis and the use of cutting-edge techniques proposed in this grant will enable me to develop as a 23 scientist and set me on a trajectory to make real and lasting impacts in the field of diabetes. This F31 award 24 includes a 2-year training plan designed to achieve 4 main objectives: 1) develop a strong comprehension of 25 techniques and concepts used in diabetes research, 2) train in the use of different microscopy techniques, 3) 26 enhance written and oral scientific communication, and 4) train in the use and handling of mouse models for 27 diabetes research. In addition, I will benefit from the collaborative research environment provided by the Center 28 for Diabetes and Metabolic Diseases at the Indiana University School of Medicine. I will also benefit from an 29 advisory committee consisting of a diverse team of carefully selected and established NIH funded investigators 30 and a supportive research environment in the laboratory. 31 32 33 34

1项目总结